Christopher Posner - 29 Feb 2024 Form 4 Insider Report for Cara Therapeutics, Inc. (TVRD)

Reporting relationship: PRESIDENT AND CEO, Director
Issuer ticker: TVRD
Reported as of: 29 Feb 2024
Net transaction value: -$5,192
SEC form: 4
Accepted by SEC: 04 Mar 2024, 16:19:05 UTC
Prior SEC filing: 12 Feb 2024
Next SEC filing: 06 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Darren DeStefano, Attorney-in-Fact

Key filing fact

Christopher Posner filed Form 4 for Cara Therapeutics, Inc. (TVRD) on 04 Mar 2024.

Key facts

This page summarizes Christopher Posner's Form 4 filing for Cara Therapeutics, Inc. (TVRD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Mar 2024, 16:19.

Change

Previous filing in this sequence was filed on 12 Feb 2024.
Current net transaction value: -$5,192.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CARA transaction

Common Stock

Sale

Transaction value: $5,192
Shares: -5,834
Change %: -3.1%
Price: $0.8900
Shares after: 180,521
Date: 29 Feb 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.